The Institute for Clinical and Economic Review (ICER) posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of biologic treatments for asthma. The scoping document will be open to public comment until 5 p.m. EST June 5.
ICER’s report is expected to include five therapies: dupilumab (Dupixent, Sanofi/Regeneron), omalizumab (Xolair, Genentech/Novartis), mepolizumab (Nucala, GlaxoSmithKline), reslizumab (Cinqair, Teva), and benralizumab (Fasenra, AstraZeneca). ICER previously reviewed mepolizumab for its use in severe eosinophilic asthma and dupilumab for its use in atopic dermatitis.
Dupilumab is currently under FDA review for use as add-on maintenance treatment in moderate-to-severe asthma, with an approval decision expected in October of 2018.
This report will be the subject of a November 2018 meeting of the Midwest Comparative Effectiveness Public Advisory Council, one of ICER’s three independent evidence appraisal committees.
To read the full press release, click here.